DB05825ExperimentalSmall molecule
NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.
- Mechanism
- Curator reviewed
NCX-1015 is the prototype of a new class of glucocorticoids, the nitro-steroids, capable of enchancing anti-inflammatory properties and reduced side effects. It also abrogates the plasma levels of a catabolite of cartilage and bone metabolism, indication of a disease modifying action.
- Primary indication
- Investigated for use/treatment in arthritis and arthritic pain and inflammatory bowel disease.Curator reviewed
- Code names
- NCX 1015
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with NCX 1015, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account